Molecular Partners (MOLN) 6-K/ACurrent report (foreign) (amended)

Filed: 17 May 24, 6:25am

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2024

Commission File Number: 001-40488

MOLECULAR PARTNERS AG

(Translation of registrant's name into English)

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

Telephone: +41 447557700

(Address of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

EXPLANATORY NOTE

The Company is furnishing this Amendment No. 1 on Form 6-K/A to its originally furnished Form 6-K on May 16, 2024 to correct the missing hyperlinks to Exhibits 99.1 and 99.2 from the original report.

This Amendment does not reflect events occurring after the filing of the Form 6-K, and does not update disclosures contained in the Form 6-K or modify or amend the Form 6-K except as specifically described in this Explanatory Note.

Molecular Partners AG (the "Company") is filing this Form 6-K to furnish (i) a press release the Company issued on
May 16, 2024 and (ii) condensed consolidated interim financial statements (unaudited) as of, and for the three months ended, March 31, 2024 (including accompanying notes thereto), which are furnished herewith as Exhibit 99.1 and 99.2, respectively.

Exhibit 99.1, 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-265960) and Form S-8 (File No. 333-272974) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


Exhibit

99.1						Press Release May 16, 2024
99.2						Condensed consolidated interim financial statements (unaudited)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Molecular Partners AG

(Registrant)

Date: May 17, 2024

/s/ PATRICK AMSTUTZ

Name:

Patrick Amstutz

Title:

Chief Executive Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.